Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Fig. 2

Schematic of the CD7 CAR structure and features of the CD7 CAR in vitro A Schematic of the CD7 CAR used in the study. B The expansion rate of CD7 CAR-transduced and nontransduced T cells in in vitro culture for 12 days after transduction (n = 3). C CD7 CAR-T cell viability at Days 7 and 12 post transduction (n = 3). D–F Surface expression of CD7 CAR in lentivirus-transduced T cells on Days 4 and 12 post transduction measured by flow cytometry (n = 3). G–I Surface expression of CD7 in lentivirus-transduced or nontransduced T cells at Days 4 and 12 post transduction measured by flow cytometry (n = 3). NTR, nontransduced. ns, not significant; **P < 0.01; ****P < 0.0001

Back to article page